Citigroup’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-42,026
| Closed | -$203K | – | 7819 |
|
|
2020
Q1 | $203K | Buy |
42,026
+31,036
| +282% | +$201K | ﹤0.01% | 4726 |
|
|
2019
Q4 | $117K | Sell |
10,990
-50,098
| -82% | -$497K | ﹤0.01% | 5632 |
|
|
2019
Q3 | $636K | Buy |
61,088
+47,193
| +340% | +$617K | ﹤0.01% | 4110 |
|
|
2019
Q2 | $213K | Buy |
13,895
+6,160
| +80% | +$89.1K | ﹤0.01% | 5210 |
|
|
2019
Q1 | $100K | Sell |
7,735
-70,222
| -90% | -$794K | ﹤0.01% | 5747 |
|
|
2018
Q4 | $741K | Buy |
77,957
+41,897
| +116% | +$543K | ﹤0.01% | 3707 |
|
|
2018
Q3 | $599K | Buy |
36,060
+15,829
| +78% | +$254K | ﹤0.01% | 4070 |
|
|
2018
Q2 | $324K | Sell |
20,231
-4,227
| -17% | -$75.5K | ﹤0.01% | 4549 |
|
|
2018
Q1 | $374K | Buy |
24,458
+23,886
| +4,176% | +$372K | ﹤0.01% | 4294 |
|
|
2017
Q4 | $9K | Buy |
572
+502
| +717% | +$6.71K | ﹤0.01% | 7093 |
|
|
2017
Q3 | $1K | Sell |
70
-172
| -71% | -$1.62K | ﹤0.01% | 7199 |
|
|
2017
Q2 | $2K | Sell |
242
-389
| -62% | -$3.24K | ﹤0.01% | 7070 |
|
|
2017
Q1 | $5K | Buy |
631
+394
| +166% | +$3.59K | ﹤0.01% | 6821 |
|
|
2016
Q4 | $3K | Hold |
237
| – | – | ﹤0.01% | 7036 |
|
|
2016
Q3 | $3K | Hold |
237
| – | – | ﹤0.01% | 6890 |
|
|
2016
Q2 | $2K | Sell |
237
-13,080
| -98% | -$82.6K | ﹤0.01% | 6946 |
|
|
2016
Q1 | $62K | Buy |
13,317
+12,889
| +3,011% | +$62.9K | ﹤0.01% | 5984 |
|
|
2015
Q4 | $2K | Sell |
428
-42
| -9% | -$341 | ﹤0.01% | 7312 |
|
|
2015
Q3 | $4K | Sell |
470
-716
| -60% | -$7.51K | ﹤0.01% | 6862 |
|
|
2015
Q2 | $14K | Sell |
1,186
-3,321
| -74% | -$46.1K | ﹤0.01% | 6306 |
|
|
2015
Q1 | $66K | Sell |
4,507
-1,719
| -28% | -$26.3K | ﹤0.01% | 5345 |
|
|
2014
Q4 | $107K | Buy |
6,226
+1,456
| +31% | +$21K | ﹤0.01% | 5189 |
|
|
2014
Q3 | $60K | Sell |
4,770
-35
| -0.7% | -$431 | ﹤0.01% | 5175 |
|
|
2014
Q2 | $71K | Sell |
4,805
-1,146
| -19% | -$17.6K | ﹤0.01% | 4915 |
|
|
2014
Q1 | $122K | Buy |
5,951
+2,619
| +79% | +$63.6K | ﹤0.01% | 4802 |
|
|
2013
Q4 | $65K | Buy |
3,332
+3,320
| +27,667% | +$88.6K | ﹤0.01% | 5571 |
|
|
2013
Q3 | $1K | Sell |
12
-210
| -95% | -$6.85K | ﹤0.01% | 6721 |
|
|
2013
Q2 | $5K | Buy |
+222
| New | +$3.54K | ﹤0.01% | 6338 |
|
Citigroup's STML Position: Q2 2020 in Review
Citigroup sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 42,026 shares — an estimated $203K sold.
Citigroup first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $741K in Q4 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Citigroup reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Citigroup sold 42,026 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $203K.
- Citigroup first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
- Citigroup's Stemline Therapeutics, Inc. position peaked at $741K in Q4 2018.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Citigroup's 13F filing for Q2 2020, filed 12 Aug 2020.